If I didn’t already own shares of Celgene (NASDAQ: CELG), it would probably be the top stock on my list to buy.
There are plenty of reasons why buying this biotech stock makes sense, including sustained growth of its blockbuster blood cancer drug. But Celgene isn’t just about Revlimid. Here are three compelling reasons to buy Celgene that have nothing to do with the company’s oncology portfolio.
